Bach T et al., 2020-10-20: Phase 1 multiple ascending dose and food-effect study of oxfendazole in 36 healthy adults at 3, 7.5 and 15 mg/kg once daily for five days, with a single 3 mg/kg dose fasted or after a fatty breakfast. Oxfendazole was well tolerated with no major safety signals; food substantially raised exposure.
Thirty-six healthy adults were enrolled in an open-label study which evaluated (i) the pharmacokinetics and safety of oxfendazole following multiple ascending doses of oxfendazole oral suspension at 3, 7.5, and 15 mg/kg once daily for 5 days
Bach T et al., 2020-10-20: Phase 1 multiple ascending dose and food-effect study of oxfendazole in 36 healthy adults at 3, 7.5 and 15 mg/kg once daily for five days, with a single 3 mg/kg dose fasted or after a fatty breakfast. Oxfendazole was well tolerated with no major safety signals; food substantially raised exposure. Study type: open-label phase 1 multiple ascending dose + food-effect study. N=36 (24 in the dose-escalation part, 12 in the food-effect part). Country: United States (University of Iowa). Route: oral suspension. Dose/schedule: 3, 7.5, 15 mg/kg once daily x 5 days; food-effect arm single 3 mg/kg fasted vs after a high-fat breakfast. Comparator: none (open-label; fasting vs fed within-subject). Funder: NIAID DMID VTEU contracts HHSN272200800008C and HHSN272201300020I plus NCATS 5U54TR001356. Conflicts: none found in the PMC text. Drug maker/supplier: not named. Registered NCT03035760. PMID 32816721. This is the study the prompt cites as 'Bach T et al., Antimicrob Agents Chemother 2020' – citation confirmed. Oxfendazole is a metabolite of fenbendazole, not fenbendazole itself.
